Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease
Patrick S. Parfrey,Robert N. Foley,Barbara H. Wittreich,Daniel J. Sullivan,Martin J. Zagari,Dieter Frei +5 more
Reads0
Chats0
TLDR
Overall adverse event rates were similar in both target groups; higher rates of skeletal pain, surgery, and dizziness were seen in the lower target group, and headache and cerebrovascular events wereseen in the higher target group.Abstract:
It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation. In this randomized, double-blind study, lower (9.5 to 11.5 g/dl) and higher (13.5 to 14.5 g/dl) hemoglobin targets were generated with epoetin α over 24 wk and maintained for an additional 72 wk. Major eligibility criteria included recent hemodialysis initiation and absence of symptomatic cardiac disease and left ventricular dilation. The primary outcome measure was left ventricular volume index (LVVI). The study enrolled 596 patients. Mean age, duration of dialysis therapy, baseline predialysis hemoglobin, and LVVI were 50.8 yr, 0.8 yr, 11.0 g/dl, and 69 ml/m 2 , respectively; 18% had diabetic nephropathy. Mean hemoglobin levels in the higher and lower target groups were 13.3 and 10.9 g/dl, respectively, at 24 wk. Percentage changes in LVVI between baseline and last value were similar (7.6% in the higher and 8.3% in the lower target group) as were the changes in left ventricular mass index (16.8 versus 14.2%). For the secondary outcomes, the only between-group difference was an improved SF-36 Vitality score in the higher versus the lower target group (1.21 versus −2.31; P = 0.036). Overall adverse event rates were similar in both target groups; higher ( Pread more
Citations
More filters
Journal Article
A cross-sectional study regarding the impact of end-stage renal disease on quality of life.
TL;DR: HD patients experience a great burden from physical and psychological symptoms of the disease, perceiving an important impairment in their quality of life, especially regarding the physical component of the SF-36.
Journal ArticleDOI
KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease
Keng T. Woo,Choong M. Chan +1 more
TL;DR: Concerns regarding the use of bisphosphonate treatment in chronic kidney disease (CKD) and adverse reports of a certain BP that works by inhibiting osteoclast-mediated bone resorption, thereby slowing the breakdown of bone to reduce the risk of fractures are shared.
Journal ArticleDOI
Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease
TL;DR: In this paper, the authors investigated associations between low hemoglobin levels and psoriasis in patients with chronic kidney disease using data from the National Health Insurance Service of Korea (NHIS).
Beneficis cardiovasculars de la correcció De L’anèmia amb eritropoetina en els malalts amb insuficiència renal crònica prediàlisi. Influència de l’estrès oxidatiu, la inflamació i el Nt-Probnp
TL;DR: L’objectiu of the present Tesis Doctoral is investigar els efectes cardiovasculars de the correccio de l’anemia durant 6 mesos of tractament amb eritropoetina, valorar the influencia of l�’estres oxidatiu, la influencia that pot tenir the inflamacio amb the hipotesi.
Journal ArticleDOI
The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry
TL;DR: Both a low ΔHb and a low post-HD Hb level were associated with a higher risk of 1-year mortality.
References
More filters
Journal ArticleDOI
Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.
TL;DR: The survey shows significant interobserver and interlaboratory variation in measurement when examining the same echoes and indicates a need for ongoing education, quality control and standardization of measurement criteria.
Journal ArticleDOI
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Anatole Besarab,W K Bolton,J K Browne,Joan C. Egrie,Allen R. Nissenson,D M Okamoto,Steve J. Schwab,David A. Goodkin +7 more
TL;DR: In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.
Journal ArticleDOI
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Robert N. Foley,Patrick S. Parfrey,Patrick S. Parfrey,John D. Harnett,John D. Harnett,Gloria M. Kent,Gloria M. Kent,Christopher J. Martin,Christopher J. Martin,David C. Murray,David C. Murray,Paul E. Barre,Paul E. Barre +12 more
TL;DR: It is concluded that clinical and echocardiographic cardiovascular disease are already present in a very high proportion of patients starting ESRD therapy and are independent mortality factors.
Journal ArticleDOI
The RAND-36 measure of health-related quality of life
Ron D. Hays,Leo S. Morales +1 more
TL;DR: This paper provides example applications of the RAND-36 cross-sectionally and longitudinally, provides information on what a clinically important difference is for the Rand-36 scales, and provides guidance for summarizing theRand-36 in a single number.
Journal ArticleDOI
Development of the Kidney Disease Quality of Life (KDQOL) Instrument
TL;DR: The KDQOLTM was administered to 165 individuals with kidney disease, sampled from nine different outpatient dialysis centres located in Southern California, the Northwest, and the Midwest, and provided support for the reliability and validity of the measure.
Related Papers (5)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more